Fatty Liver Symptoms: Signs, Causes and What Helps
Updated
Fatty liver symptoms are usually absent: most people with fatty liver disease feel well, and the condition is found by chance on a blood test or scan done for another reason. When symptoms do appear, they tend to be vague, such as tiredness or a dull discomfort under the right ribs. Yellow skin or eyes, a swollen abdomen or legs, and confusion are different: they are signs of advanced liver damage and need urgent care. This guide explains what fatty liver disease is, including its new name MASLD, the symptoms it can cause, the warning signs of cirrhosis, the causes and risk factors, how doctors find it and check for scarring with FIB-4 and elastography, its stages, what helps, and when to see a doctor. Every figure links to the guideline or health service page it comes from.
- Usual symptomsNone; sometimes tiredness or discomfort under the right ribs
- Urgent signsYellow skin or eyes, swelling, confusion, vomiting blood, black stools
- Main causesExcess weight, type 2 diabetes, high blood fats, alcohol
- What helpsWeight loss of 3–5% reduces liver fat; more than 10% for scarring (AASLD 2023)
What is fatty liver disease?
Fatty liver disease is a build-up of excess fat in the liver, and doctors now call its most common form metabolic dysfunction-associated steatotic liver disease, or MASLD, the name that replaced nonalcoholic fatty liver disease (NAFLD) in 2023. A multisociety consensus published in Hepatology chose steatotic liver disease as the umbrella term and defined MASLD as liver fat together with at least one of five cardiometabolic risk factors: a raised body mass index or waist size, raised blood sugar or type 2 diabetes, high blood pressure, high triglycerides, or low HDL cholesterol. People with MASLD who also drink more alcohol, from 140 g a week for women or 210 g for men, are described as having MetALD, and fat caused mainly by heavy drinking is alcohol-related liver disease. The US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that about 24% of US adults have MASLD, and the 2023 AASLD practice guidance puts adult prevalence at 25% to 30%.
The inflamed form of MASLD is metabolic dysfunction-associated steatohepatitis (MASH), the new name for nonalcoholic steatohepatitis (NASH). The NIDDK explains that most people with MASLD have fat with little or no inflammation, which typically doesn't progress to liver damage, while MASH can lead to scarring, cirrhosis and liver cancer.
What are the symptoms of fatty liver?
Fatty liver usually causes no symptoms at all. The NIDDK calls it a silent disease with few or no symptoms, the NHS says it does not usually cause any symptoms, and the 2023 AASLD guidance notes that in most patients it causes no symptoms or only vague ones, which is why so many cases go undiagnosed. When symptoms do occur, the two most often described are tiredness and discomfort in the upper right side of the abdomen, under the ribs, where the liver sits; the NHS adds feeling generally unwell. These symptoms are not specific, because tiredness and a dull ache have many other causes, and they say little about how much damage is present. The NIDDK points out that people may still have no symptoms even after fatty liver has progressed to cirrhosis. A lack of symptoms is therefore not a reason to skip a check when risk factors such as type 2 diabetes, obesity or regular drinking are present.
- Most common: no symptoms at all; the fat is found on a blood test or scan.
- Possible in fatty liver (MASLD): tiredness, feeling generally unwell, and pain or discomfort under the right ribs (NHS, NIDDK).
- Possible in alcohol-related liver disease: tiredness, reduced appetite, weight loss without trying, and feeling or being sick (NHS).
What are the signs of advanced fatty liver disease?
Signs of advanced fatty liver disease appear when long-standing inflammation has scarred the liver into cirrhosis, and they are a reason to get medical care quickly. The NHS lists early symptoms of cirrhosis as feeling tired or unwell all the time, loss of appetite or weight loss without trying, feeling or being sick, tummy pain, visible blood vessels on the skin and blotchy red palms. Later signs include yellow skin and whites of the eyes (jaundice), itchy skin, bleeding or bruising easily, a swollen abdomen, legs, ankles or feet, trembling hands, slurred speech, and confusion or difficulty concentrating. The NHS page on alcohol-related liver disease names jaundice, swelling of the abdomen or legs, and confusion as its later symptoms too. These signs mean the liver is struggling to do its work, a stage called decompensation, and the 2023 AASLD guidance reports that people with cirrhosis progress to decompensation at rates of 3% to 20% a year.
- Emergency care now: vomiting blood, very dark or black stools, or sudden confusion or slurred speech (NHS). Don't drive yourself; call an ambulance or ask someone to take you.
- Urgent same-day advice: new yellowing of the skin or eyes, a swollen abdomen, legs, ankles or feet, or more shortness of breath than usual (NHS).
- Soon, with your doctor: lasting tiredness, appetite or weight loss you can't explain, easy bruising or itchy skin.
What causes fatty liver, and who is at risk?
Fatty liver is caused mainly by metabolic risk factors or by alcohol, and often by both together. For MASLD, the NIDDK lists overweight or obesity, insulin resistance or type 2 diabetes, abnormal blood fats such as high triglycerides, and metabolic syndrome, and notes that certain genes make fatty liver more likely. The NHS adds fat around the stomach and waist, a less healthy diet or low physical activity, polycystic ovary syndrome, high blood pressure or cholesterol, and being over 50. The figures are high: the NIDDK estimates that up to 75% of people with overweight and more than 90% of people with severe obesity have fatty liver, and the AASLD guidance reports it in 30% to 75% of people with type 2 diabetes, the risk factor it calls the most impactful for developing fatty liver, for fibrosis progression and for liver cancer. Less common causes include rapid weight loss, malnutrition and some medicines, among them corticosteroids, HIV treatment and estrogens.
Alcohol works on its own and alongside metabolic risk. Fatty liver is the first stage of alcohol-related liver disease, and the AASLD guidance states that in people with MASLD, alcohol can be a cofactor for disease progression, so intake should be assessed regularly. The NIDDK notes that a person can have both kinds of fatty liver at the same time, which is the reason the new MetALD category exists.
Medicines are one cause that is easy to overlook, and checking them takes time, because the evidence sits in long drug labels and scattered case reports. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. Instead of answering from memory, it searches journals, clinical guidelines and drug labels first, then writes an answer with a link after every claim. Ask it whether a medicine you take, such as a corticosteroid, has been linked to fatty liver, and the answer points to the label section or study it comes from, so you can raise it with your prescriber rather than stopping anything on your own.
Ask AskMed whether one of your medicines affects the liver:
How is fatty liver found and checked?
Fatty liver is usually found by chance: the NHS says it is usually diagnosed after blood tests or scans done for another reason, such as a raised ALT on routine bloods or an ultrasound that shows a fatty liver. Liver enzymes are an imperfect clue, because the 2023 AASLD guidance warns that they are frequently normal in people with advanced disease, and standard ultrasound misses smaller amounts of fat, so the guidance does not recommend it as a tool for detecting fatty liver. What matters most is scarring rather than fat, and the AASLD advises a FIB-4 check for everyone with fatty liver or suspected fatty liver. FIB-4 combines age, AST, ALT and platelet count: below 1.3 means a low risk of advanced fibrosis, 1.3 to 2.67 is intermediate and above 2.67 is high. When FIB-4 is 1.3 or higher, the guidance suggests a liver stiffness test such as vibration-controlled transient elastography (VCTE, often known as FibroScan), magnetic resonance elastography or the ELF blood test.
- Found by chance: a raised ALT, or fat seen on a scan done for another reason.
- Other causes ruled out: alcohol intake, medicines, viral hepatitis and other liver conditions.
- FIB-4: under 1.3 is low risk of advanced fibrosis; 1.3 or higher needs a second test.
- Liver stiffness: under 8 kPa on VCTE rules out advanced fibrosis; over 12 kPa makes it likely and calls for a specialist.
On VCTE, the AASLD guidance says a liver stiffness below 8 kPa can be used to rule out advanced fibrosis, 8 to 12 kPa may be associated with fibrotic MASH, and above 12 kPa is associated with a high likelihood of advanced fibrosis. The same scan can report a controlled attenuation parameter (CAP), which the guidance accepts as a point-of-care measure of liver fat; MRI proton density fat fraction can measure the fat more precisely. You can work out the score with the FIB-4 calculator, and the guide to elevated ALT levels explains what a raised ALT on its own does and doesn't mean.
Reports are where many people get stuck: an ultrasound that says "increased echogenicity", a normal ALT, and a FIB-4 of 1.5 can seem to point in different directions. AskMed lets you describe the whole picture, such as a fatty liver on ultrasound with a FIB-4 of 1.5 in someone with type 2 diabetes, and ask what the guidelines suggest next. The answer sets out the AASLD steps for that result, each linked to the guidance and its year, so you can check it against the plan your own doctor proposes.
Check what a FIB-4 or FibroScan result means in AskMed:
What are the stages of fatty liver disease?
Fatty liver disease has four stages, and the NHS describes them as simple fatty liver (steatosis), steatohepatitis (MASH, previously called NASH), fibrosis and cirrhosis. Most people only ever have the first stage, which does not usually cause problems. In MASH the fat comes with inflammation and liver cell injury; over years this can lay down scar tissue (fibrosis), and widespread scarring with nodules is cirrhosis. MASH is not rare even in people who feel well: the 2023 AASLD guidance cites a study that found it in 14% of adults without symptoms who were having colon cancer screening. The guidance names fibrosis and steatohepatitis as the main predictors of disease progression, and fibrosis as the main driver of poor outcomes. In a prospective study of 1,773 patients it describes, deaths from any cause ran at 0.32 per 100 person-years with fibrosis stages 0 to 2, 0.89 with bridging fibrosis and 1.76 with cirrhosis. Cirrhosis also brings a risk of liver cancer.
Fatty liver also matters beyond the liver. The NIDDK and the AASLD guidance both name cardiovascular disease as the most common cause of death in people with fatty liver so blood pressure, cholesterol and diabetes care are part of treatment. The AASLD calls statins safe and recommended for heart risk across the disease spectrum, including compensated cirrhosis.
What helps fatty liver?
What helps fatty liver most is weight loss, a healthier diet, more physical activity and less alcohol, and the 2023 AASLD guidance gives the targets. Weight loss of 3% to 5% of body weight improves liver fat, but greater weight loss, generally more than 10%, is required to improve MASH and fibrosis, and the guidance says the benefit grows with the amount lost. For people with overweight it advises a diet that creates a calorie deficit, ideally limited in carbohydrates and saturated fat and rich in fiber and unsaturated fats, as in the Mediterranean diet, for its added heart benefits. Exercise helps even without weight loss: studies in the guidance found that moderate exercise at least five times a week, for a total of 150 minutes, or adding more than 60 minutes of activity a week, could prevent or improve fatty liver. The guidance adds that drinking coffee, with or without caffeine, has been linked to less fibrosis in observational studies.
Alcohol
For alcohol-related fatty liver, the NHS says the liver can usually recover if you stop drinking, while cirrhosis usually can't be reversed. For MASLD, the AASLD guidance advises that people with clinically significant fibrosis (stage F2 or higher) should avoid alcohol completely, and that stopping may lower the risk of fibrosis progression and of liver and other cancers. The NHS advises people with MASLD to keep to the UK limit of no more than 14 units a week, and not to smoke.
Medicines for MASH with fibrosis
For most people with fatty liver, lifestyle change is the treatment, but two medicines are now approved in the United States for adults with MASH and moderate to advanced fibrosis who do not have cirrhosis, both to be used alongside diet and exercise. The US Food and Drug Administration (FDA) approved resmetirom (Rezdiffra) on March 14, 2024, as the first treatment for liver scarring due to fatty liver disease, and in August 2025 it granted accelerated approval to semaglutide (Wegovy) for the same group. Specialists may also consider other options in selected people, and the NHS mentions pioglitazone or vitamin E under specialist care. Whether any medicine fits depends on the stage of fibrosis, other conditions and other medicines, so the decision belongs with a liver specialist.
The approvals are recent, and the rules on who qualifies are spread across FDA announcements, labels and guideline updates. AskMed can pull them together: ask which people the resmetirom and semaglutide approvals cover, what fibrosis stage they require and what trial results they were based on, and the answer cites the FDA announcement, label and trial papers it draws on, so you can prepare questions for a hepatology appointment.
Ask AskMed about the new MASH treatments:
When should you see a doctor about fatty liver?
You should see a doctor about fatty liver if you think you may have it or are at higher risk, which is the NHS advice, and especially if you have type 2 diabetes, obesity with other health problems, a family history of cirrhosis, or drink more than lightly. The 2023 AASLD guidance does not advise screening the whole population, but it says these high-risk groups should be checked for advanced fibrosis, and that close relatives of people with MASH cirrhosis should be told about their own higher risk and offered screening. A doctor will usually ask about alcohol and medicines, measure weight and waist, arrange blood tests including a FIB-4 score, and may order an ultrasound or a liver stiffness test. Seek care the same day for yellowing of the skin or eyes, or new swelling of the abdomen or legs. Call an ambulance or go to an emergency department for vomiting blood, very dark or black stools, or sudden confusion or drowsiness.
Frequently asked questions
Can fatty liver cause pain?
Sometimes. Fatty liver can cause a dull discomfort under the right ribs, but most people feel nothing. Severe or worsening abdominal pain, especially with vomiting blood, black stools or confusion, needs emergency care.
Can fatty liver be reversed?
Often, yes. The AASLD guidance says losing 3% to 5% of body weight improves liver fat and more than 10% is generally needed to improve inflammation and fibrosis. With alcohol-related fatty liver, the NHS says the liver can usually recover if you stop drinking. Cirrhosis usually can't be reversed.
Can you have fatty liver with normal liver tests?
Yes. The AASLD guidance says liver enzymes such as ALT are frequently normal even in advanced fatty liver disease, so a normal result doesn't rule it out. FIB-4 and liver stiffness tests check for scarring.
Is fatty liver serious?
For most people it stays at the first stage and doesn't cause problems. It becomes serious when inflammation leads to fibrosis and cirrhosis. Cardiovascular disease is the most common cause of death in people with fatty liver, so heart health matters too.
What is the difference between MASLD and NAFLD?
They describe the same condition. In 2023 a multisociety consensus renamed nonalcoholic fatty liver disease (NAFLD) as metabolic dysfunction-associated steatotic liver disease (MASLD), and NASH became MASH. The new definition requires at least one cardiometabolic risk factor.
Sources
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
- Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. Summary: AASLD, New MASLD nomenclature.
- National Institute of Diabetes and Digestive and Kidney Diseases. Definition & Facts of NAFLD & NASH.
- National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & Causes of NAFLD & NASH.
- NHS. Non-alcoholic fatty liver disease (NAFLD).
- NHS. Alcohol-related liver disease (ARLD).
- NHS. Cirrhosis.
- US Food and Drug Administration. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. March 14, 2024.
- AJMC. FDA Approves Semaglutide for MASH With Fibrosis. August 18, 2025.
